https://pittplusme.org/study/psoriasisgene
Moderate to Severe Plaque Psoriasis Study
STUDY BASICS
Do you have plaque psoriasis? You may be eligible for a research study to understand the effect of bimekizumab on how genes are expressed in the skin of participants who have plaque psoriasis alone or with psoriatic arthritis. Compensation is provided.
STUDY PURPOSE
The purpose of this open-label study is to help us understand the effect of bimekizumab on how genes are expressed in the skin of participants who have plaque psoriasis alone or with psoriatic arthritis. This will help us understand further how bimekizumab acts in your body and how your body responds to bimekizumab. Open-label means that both you and your study doctor will know that you are receiving bimekizumab and at what dose.
COULD THIS STUDY BE RIGHT FOR YOU?
- Age 18 years of age or older
- Have moderate to severe plaque psoriasis
WHAT PARTICIPANTS CAN EXPECT
The duration of the study will be up to 2 years with up to a total of 20 visits to the clinic.
- Screening Period (2 to 5 weeks)
- Run-In Study Treatment Period (48 weeks) to see how your skin (and joint) responds to bimekizumab - you will receive the study treatment every 4 weeks up to Week 16 and then every 8 weeks up to Week 48
- At week 48, you will either enter in either the Randomized Study Treatment‑Extension Period or the Study Treatment-Extension Period depending on your psoriasis/psoriatic arthritis status:
- Randomized Study Treatment‑Extension Period - randomly allocated (like flipping a coin or throwing dice) in a 1:1 ratio to receive either bimekizumab 320 mg every 8 weeks or bimekizumab 320 mg every 12 weeks
- Study Treatment-Extension Period - receive bimekizumab 320 mg every 8 weeks
IRB: SSU00263805
- UCB Biopharma SRL - PS0039 / 279229, A phase 3b exploratory multicenter open-label study to evaluate the effect of bimekizumab on gene expression biomarkers in study participants with moderate to severe plaque psoriasis (Pro00077926)
MEET THE RESEARCHER
Joe K. Tung
Joe K. Tung, MD, MBA received his undergraduate degree in Molecular Biophysics and Biochemistry at Yale University and his medical degree at Harvard Medical School. He concurrently obtained his Master of Business Administration from Harvard Business School, graduating in the top 5% as a Baker Scholar. Dr. Tung went on to complete his internal medicine intern year at the Brigham and Women's Hospital and his dermatology residency at the University of Pittsburgh Medical Center.
Dr. Tung won a gold medal representing the United States at the 43rd International Chemistry Olympiad. His basic science and clinical research work have resulted in multiple peer-reviewed articles, reviews, textbook chapters, clinical decision support tools, and presentations at national and international meetings. He serves as a reviewer for research journals, as a consultant for pharmaceutical and biotechnology companies, as a principal investigator for global industry-sponsored clinical trials, and as an advisor for multiple healthcare start-ups. In his spare time, Dr. Tung enjoys traveling, playing golf, rock climbing, visiting museums, and attending live sporting events.